Enliven Therapeutics [ELVN] vs Liquidia [LQDA] Detailed Stock Comparison
Enliven Therapeutics
NASDAQ
Loading...
Liquidia
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Enliven Therapeutics wins in 7 metrics, Liquidia wins in 8 metrics, with 0 ties. Liquidia appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Enliven Therapeutics | Liquidia | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.38 | -13.51 | Liquidia |
| Price-to-Book Ratio | 2.38 | 126.72 | Enliven Therapeutics |
| Debt-to-Equity Ratio | 0.12 | 1,319.26 | Enliven Therapeutics |
| PEG Ratio | -0.53 | -0.42 | Enliven Therapeutics |
| EV/EBITDA | -5.90 | -14.31 | Liquidia |
| Profit Margin (TTM) | 0.00% | 58.00% | Liquidia |
| Operating Margin (TTM) | 0.00% | -424.41% | Enliven Therapeutics |
| Return on Equity | -25.26% | -389.13% | Enliven Therapeutics |
| Return on Assets (TTM) | -17.19% | -39.74% | Enliven Therapeutics |
| Free Cash Flow (TTM) | $-73.24M | $-101.87M | Enliven Therapeutics |
| 1-Year Return | -27.27% | 106.13% | Liquidia |
| Price-to-Sales Ratio (TTM) | N/A | 99.94 | N/A |
| Enterprise Value | $671.69M | $1.96B | Liquidia |
| EV/Revenue Ratio | N/A | 101.34 | N/A |
| Gross Profit Margin (TTM) | N/A | 83.06% | N/A |
| Revenue per Share (TTM) | $0 | $0 | Liquidia |
| Earnings per Share (Diluted) | $-1.99 | $-1.82 | Liquidia |
| Beta (Stock Volatility) | 1.03 | 0.16 | Liquidia |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Enliven Therapeutics vs Liquidia Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Enliven Therapeutics | -0.94% | 0.00% | 1.40% | 3.62% | 13.60% | -15.06% |
| Liquidia | 5.12% | 0.26% | -18.30% | 83.61% | 83.91% | 88.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Enliven Therapeutics | -27.27% | 435.62% | 4.26% | 26.88% | 26.88% | 26.88% |
| Liquidia | 106.13% | 328.89% | 699.30% | 108.01% | 108.01% | 108.01% |
News Based Sentiment: Enliven Therapeutics vs Liquidia
Enliven Therapeutics
News based Sentiment: POSITIVE
The $150 million Series C financing is a significant event for Enliven Therapeutics, providing the company with the resources to advance its clinical pipeline and expand its research efforts. This funding round signals strong investor confidence and reduces near-term financial risk, making it a positive development for investors.
Liquidia
News based Sentiment: MIXED
Liquidia is facing both opportunities and challenges this month. The potential expansion into the IPF market is a positive catalyst, but the ongoing patent litigation with United Therapeutics and bearish options trading activity introduce significant uncertainty. This creates a mixed investment narrative.
Performance & Financial Health Analysis: Enliven Therapeutics vs Liquidia
| Metric | ELVN | LQDA |
|---|---|---|
| Market Information | ||
| Market Cap | $1.17B | $1.93B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 377,400 | 3,320,420 |
| 90 Day Avg. Volume | 552,057 | 2,676,227 |
| Last Close | $20.11 | $24.03 |
| 52 Week Range | $13.30 - $30.03 | $9.71 - $29.94 |
| % from 52W High | -33.03% | -19.74% |
| All-Time High | $62.71 (Jun 08, 2020) | $38.46 (Oct 08, 2018) |
| % from All-Time High | -67.93% | -37.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 1.42% |
| Quarterly Earnings Growth | N/A | 1.42% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.58% |
| Operating Margin (TTM) | 0.00% | -4.24% |
| Return on Equity (TTM) | -0.25% | -3.89% |
| Debt to Equity (MRQ) | 0.12 | 1,319.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.25 | $0.18 |
| Cash per Share (MRQ) | $8.28 | $2.01 |
| Operating Cash Flow (TTM) | $-70,580,000 | $-116,055,000 |
| Levered Free Cash Flow (TTM) | $-52,711,624 | $-71,345,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Enliven Therapeutics vs Liquidia
| Metric | ELVN | LQDA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.38 | -13.51 |
| Forward P/E | -8.27 | -14.38 |
| PEG Ratio | -0.53 | -0.42 |
| Price to Sales (TTM) | N/A | 99.94 |
| Price to Book (MRQ) | 2.38 | 126.72 |
| Market Capitalization | ||
| Market Capitalization | $1.17B | $1.93B |
| Enterprise Value | $671.69M | $1.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 101.34 |
| Enterprise to EBITDA | -5.90 | -14.31 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.16 |
| Book Value per Share (MRQ) | $8.25 | $0.18 |
Financial Statements Comparison: Enliven Therapeutics vs Liquidia
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ELVN | LQDA |
|---|---|---|
| Revenue/Sales | $0 | $3.12M |
| Cost of Goods Sold | N/A | $1.52M |
| Gross Profit | N/A | $1.60M |
| Research & Development | $21.49M | $6.97M |
| Operating Income (EBIT) | $-28.58M | $-35.43M |
| EBITDA | $-28.50M | $-33.25M |
| Pre-Tax Income | $-25.34M | $-38.37M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-25.34M | $-38.37M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ELVN | LQDA |
|---|---|---|
| Cash & Equivalents | $101.71M | $169.76M |
| Total Current Assets | $294.32M | $177.21M |
| Total Current Liabilities | $13.97M | $60.52M |
| Long-Term Debt | N/A | $109.66M |
| Total Shareholders Equity | $288.30M | $49.71M |
| Retained Earnings | $-272.02M | $-595.76M |
| Property, Plant & Equipment | $1.78M | $11.49M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ELVN | LQDA |
|---|---|---|
| Operating Cash Flow | $-16.74M | $-26.68M |
| Capital Expenditures | $-139,000 | $-330,000 |
| Free Cash Flow | $-17.20M | $-31.01M |
| Debt Repayment | N/A | $-2.19M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ELVN | LQDA |
|---|---|---|
| Shares Short | 4.86M | 18.47M |
| Short Ratio | 10.25 | 7.92 |
| Short % of Float | 0.12% | 0.27% |
| Average Daily Volume (10 Day) | 377,400 | 3,320,420 |
| Average Daily Volume (90 Day) | 552,057 | 2,676,227 |
| Shares Outstanding | 48.94M | 84.68M |
| Float Shares | 36.35M | 60.86M |
| % Held by Insiders | 0.08% | 0.13% |
| % Held by Institutions | 1.04% | 0.71% |
Dividend Analysis & Yield Comparison: Enliven Therapeutics vs Liquidia
| Metric | ELVN | LQDA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |